Jackie Fouse is stepping down as CEO of Agios Pharmaceuticals, replaced by Brian Goff, a former executive with Alexion Pharmaceuticals, the company announced Tuesday. Fouse will remain with Agios as its new board chairperson.
Agios is framing the management reshuffle as the latest in a series of deliberate, strategic decisions to bolster the company’s future by pivoting toward the development of drugs for genetically-defined diseases. But investors, already wary of some of the company’s recent moves, may interpret Fouse’s decision to vacate the CEO post as another sign Agios’s plan is not working.
“I view this as a terrific opportunity for me to take on a different role but stay in the Agios team after what’s been a very eventful three and a half years,” Fouse said in an interview with STAT.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
